Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936.
D000328:Adult; D000368:Aged; D001499:Bayes Theorem; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D004768:Enterotoxins / Q000008:administration & dosage* / Q000276:immunology; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007369:Interferon Inducers / Q000008:administration & dosage* / Q000276:immunology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D015233:Models, Statistical; D018089:Superantigens / Q000008:administration & dosage* / Q000276:immunology
D004768:Enterotoxins; D007369:Interferon Inducers; D018089:Superantigens; C026066:enterotoxin A, Staphylococcal